| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Kane Biotech Inc (2): Kane Biotech highlights data on revyve biofilm action | 2 | Stockwatch | ||
| KANE BIOTECH Aktie jetzt für 0€ handeln | |||||
| 17.03. | Kane Biotech Inc.: Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms | 2 | GlobeNewswire (USA) | ||
| 10.03. | Kane Biotech Inc (2): Kane Biotech signs with U.S. gov't distributor | 1 | Stockwatch | ||
| 10.03. | Kane Biotech Inc.: Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership | 1 | GlobeNewswire (USA) | ||
| 20.02. | Kane Biotech Inc (2): Kane publishes article in International Wound Journal | 3 | Stockwatch | ||
| 20.02. | Kane Biotech Inc.: Kane Biotech Announces Publication of revyve Wound Gel Article in the International Wound Journal | 1 | GlobeNewswire (USA) | ||
| 19.02. | Kane Biotech Inc (2): Kane Biotech adds U.S. distributors for revyve products | 1 | Stockwatch | ||
| 19.02. | Kane Biotech Inc.: Kane Biotech Expands Commercial Activities in the United States | 712 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has signed non-exclusive distribution/sales agreements... ► Artikel lesen | |
| 17.02. | Kane Biotech Inc (2): Kane Biotech passes regulatory "milestones" | 1 | Stockwatch | ||
| 17.02. | Kane Biotech Inc.: Kane Biotech Announces FDA 510(k) Clearance for revyve Antimicrobial Skin and Wound Cleanser | 490 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) ("Kane Biotech". "Kane" or the "Company") today announces two regulatory milestones that strengthen the Company's... ► Artikel lesen | |
| 12.02. | Kane Biotech Inc (2): Kane Biotech revives commercial activity for revyve gel | 1 | Stockwatch | ||
| 12.02. | Kane Biotech Inc.: Kane Biotech Restarts Commercial Activities and Strengthens North American Management | 371 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces the resumption of commercial activities in both the United... ► Artikel lesen | |
| 30.12.25 | Kane Biotech Inc (2): Kane Biotech 14-million-share private placement | 2 | Stockwatch | ||
| 18.12.25 | Kane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company | 1 | GlobeNewswire (USA) | ||
| 17.12.25 | Kane Biotech Inc.: Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 10.12.25 | Kane Biotech Inc.: Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | Kane Biotech Inc (2): Kane Biotech loses $607,345 in Q3 2025 | 1 | Stockwatch | ||
| 28.11.25 | Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2025 Financial Results | 736 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its third quarter 2025 financial results. Third Quarter... ► Artikel lesen | |
| 27.11.25 | Kane Biotech Inc (2): Kane Biotech arranges $800,000 private placement | 1 | Stockwatch | ||
| 27.11.25 | Kane Biotech Inc.: Kane Biotech Announces New Private Placement Offering | 2 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,074 | +19,03 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NANOREPRO | 1,340 | -4,29 % | NanoRepro: Strukturelle Stärkung im Kerngeschäft | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die NanoRepro AG in den ersten sechs Monaten des Geschäftsjahres 2025 (per 30.6.) den Umsatz deutlich um rund 37... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,650 | -11,19 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRAIN BIOTECH | 2,460 | +1,23 % | BRAIN BIOTECH AG: Stabilität als strategische Phase | ||
| AAP IMPLANTATE | 1,360 | -0,73 % | AAP Implantate AG - Schwächer, aber nicht richtungslos | ||
| CO.DON | 0,014 | -22,22 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 1,190 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| CLINUVEL | 5,960 | +1,79 % | Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy | Original-Research: CLINUVEL Pharmaceuticals Limited - from Parmantier & Cie. GmbH
26.03.2026 / 12:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,276 | +3,76 % | Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks | ||
| BIO-GATE | 0,630 | +3,28 % | BIO-GATE AG zeigt fundamentale Stärke | ||
| COSCIENS BIOPHARMA | 0,770 | -0,65 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,949 | -0,10 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report |